Recent briefings through mid-September 2026 recorded no material discrete corporate events, new regulatory disclosures, or new corporate announcements for AbbVie Inc. beyond routine administrative filings. Successive briefs dated through 2026-09-11 and 2026-09-19 each confirmed the absence of new substantive filings or corporate actions during the covered periods [Brief - 2026-09-19] [Brief - 2026-09-11].
As of the quarter ending 2026-06-30, AbbVie reported trailing twelve-month revenue of $64.39 billion, representing year-over-year growth of 10.16%. Net income on a TTM basis stood at $6.31 billion, with a net margin of 9.80% and an operating margin of 26.20%. Gross margin was recorded at 65.73%. EPS on a year-over-year basis rose 290.38%, while the P/E ratio stood at 74.67. The company held $6.57 billion in cash against total debt of $64.50 billion [SEC 10-Q - ABBV - 2026-06-30].
Institutional ownership data reflects significant position changes among several large filers. Citadel added 76% to its existing position, and AQR Capital increased its holding by 127%, representing the largest proportional addition among the reported filers. Millennium also added 35% to its position. Conversely, Bridgewater reduced its position by 61% during the same reporting period. These divergent moves across major institutional holders constitute the primary trigger for this report [SEC 13F - Citadel - Q2 2026] [SEC 13F - AQR Capital - Q2 2026] [SEC 13F - Millennium - Q2 2026] [SEC 13F - Bridgewater - Q2 2026].
The prevailing macro environment features a 10-year US Treasury yield of 5.18% and a 2-year yield of 4.87%, producing a normal yield curve spread of approximately 31 basis points [FRED DGS10] [FRED DGS2]. This rate environment represents the broader fixed-income backdrop against which AbbVie's $64.50 billion total debt load is contextualised as of the most recent quarterly filing.